Orexigen Therapeutics (OREX) Tops Q3 EPS by 78c, Miss on Revenues

Orexigen Therapeutics (NASDAQ: OREX) reported Q3 EPS of ($1.35), $0.78 better than the analyst estimate of ($2.13). Revenue for the quarter came in at $18.9 million versus the consensus estimate of $24.2 million.

For earnings history and earnings-related data on Orexigen Therapeutics (OREX) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Femasys Inc. (FEMY) Misses Q2 EPS by 20c
• Is Treasury selloff a major issue for stock market bulls?